Bortezomib downregulates NF-κB signalling (activation of which has been implicated in the progression of many cancers) by reversibly binding the 20S subunit active site and preventing proteasomal degradation of inhibitors of NF-κB (IκBs) [12,35,46]. Here, NFKB1 is linked to cancer.